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Abstract
Background: FU is the human homologue of the Drosophila gene fused whose product fused is a positive
regulator of the transcription factor Cubitus interruptus (Ci). Thus, FU may act as a regulator of the human
counterparts of Ci, the GLI transcription factors. Since Ci and GLI are targets of Hedgehog signaling in
development and morphogenesis, it is expected that FU plays an important role in Sonic, Desert and/or
Indian Hedgehog induced cellular signaling.
Results: The FU gene was identified on chromosome 2q35 at 217.56 Mb and its exon-intron organization
determined. The human developmental disorder Syndactyly type 1 (SD1) maps to this region on
chromosome 2 and the FU coding region was sequenced using genomic DNA from an affected individual
in a linked family. While no FU mutations were found, three single nucleotide polymorphisms were
identified. The expression pattern of FU was thoroughly investigated and all examined tissues express FU.
It is also clear that different tissues express transcripts of different sizes and some tissues express more
than one transcript. By means of nested PCR of specific regions in RT/PCR generated cDNA, it was
possible to verify two alternative splicing events. This also suggests the existence of at least two additional
protein isoforms besides the FU protein that has previously been described. This long FU and a much
shorter isoform were compared for the ability to regulate GLI1 and GLI2. None of the FU isoforms
showed any effects on GLI1 induced transcription but the long form can enhance GLI2 activity. Apparently
FU did not have any effect on SUFU induced inhibition of GLI.
Conclusions: The FU gene and its genomic structure was identified. FU is a candidate gene for SD1, but
we have not identified a pathogenic mutation in the FU coding region in a family with SD1. The sequence
information and expression analyses show that transcripts of different sizes are expressed and subjected
to alternative splicing. Thus, mRNAs may contain different 5'UTRs and encode different protein isoforms.
Furthermore, FU is able to enhance the activity of GLI2 but not of GLI1, implicating FU in some aspects
of Hedgehog signaling.
Published: 22 July 2004
BMC Genomics 2004, 5:49 doi:10.1186/1471-2164-5-49
Received: 22 March 2004
Accepted: 22 July 2004
This article is available from: http://www.biomedcentral.com/1471-2164/5/49
© 2004 Østerlund et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genomics 2004, 5:49 http://www.biomedcentral.com/1471-2164/5/49
Page 2 of 10
(page number not for citation purposes)
Background
The signaling molecule Hedgehog (Hh) and components
of its intracellular signaling pathway have been the subject
of intensive research in several species from fruit fly to
man during recent years. Numerous developmental and
morphogenic processes are controlled by the Hedgehog
family of proteins. Much effort has been directed at iden-
tifying components of the signaling pathway and their
respective roles and interactions [for an extensive review
see [1]]. In Drosophila, Hh signaling to the transcription
factor Cubitus interruptus (Ci) is mediated by a protein
complex consisting of Ci and three other cytosolic pro-
teins. These are the costal 2 (cos2), suppressor of fused
(su(fu)) and fused (fu), where fu is a kinase domain con-
taining protein with positive regulatory activities in Hh
induction of Ci mediated transcriptional activation. Hh
binds to its receptor patched (ptc), a 12 membrane span-
ning protein, leading to the activation of another mem-
brane protein smoothened (smo) [2,3]. Smo is a 7
transmembrane protein that, by an unknown mechanism,
signals to the Ci containing protein complex leading to
activation of Ci. Vertebrate homologues of these Dro-
sophila genes and proteins have been identified during the
last decade. To a large extent the signaling pathway has
been conserved in vertebrates. However, the picture is
more complicated since some of the Drosophila genes have
two or more vertebrate homologues. There are three Ci
homologues in vertebrates, GLI1, GLI2 and GLI3. GLI1
has activation properties whereas GLI2 and GLI3 have
both activation and repression activities [reviewed in [4]].
It is expected that the human homologue of fu (FU) is a
positive regulator of GLI proteins, whereas the su(fu)
homologue SUFU is a negative regulator. It has been
shown by several groups that SUFU inhibits both GLI1
and GLI2 transcriptional activity and has major effects on
the shuttling between cytosol and nucleus [5-7]. In a sim-
ilar way it was shown in C3H/10T½ cells that FU is a pos-
itive regulator of GLI2 but with little effect on GLI1 [8]. FU
is a 1315 residue protein with high similarity to fu in the
N-terminal kinase domain.
Interestingly, it was discovered that mutations in PTCH1,
the human counterpart of ptc, underlie the Nevoid Basal
Cell Carcinoma Syndrome (NBCCS) [9,10]. Patients with
NBCCS (also known as Gorlin syndrome) have develop-
mental abnormalities and eventually develop basal cell
carcinoma (BCC) and other tumors like medulloblastoma
and rhabdomyosarcoma [11,12]. Also SMO  and SUFU
mutations as well as overexpression of GLI1 or GLI2 can
lead to BCC or medulloblastoma [13-16]. Thus, investiga-
tions of this signaling pathway, its genes and protein com-
ponents, is not only important for understanding
development and morphogenesis, but also for cancer
biology.
Here three FU cDNA clones have been identified and used
for sequence analysis, identification and structural
description of the FU gene, as well as for construction and
subcloning of FU expression vectors. Using the available
public databases the FU gene was found to be present in a
sequenced BAC clone from chromosome 2. FU is located
in the same region of chromosome 2q34-q36 to which
the human limb malformation disorder Syndactyly type 1
(SD1) has recently been mapped in a large German pedi-
gree [17] and confirmed in an Iranian family [18]. Its pos-
sible association with this condition was investigated by
sequencing the coding exons of the FU gene in an affected
member from the German family [17]. The tissue expres-
sion pattern of FU has been determined using an RNA
array and Northern blots. FU is expressed in all 72 tested
tissues. It is clear that not only a single transcript is
expressed. Instead transcripts of different sizes are seen
and some tissues apparently express more than one major
transcript. From the genomic structure and the cDNA
clones it was possible to predict several alternative splic-
ing events and consequently the likely expression of dif-
ferent protein isoforms. Two of the isoforms were
expressed in HEK293 cells and tested for their ability to
regulate the activity of GLI1 and GLI2, showing positive
effects on GLI2 but not on GLI1.
Results
Chromosomal localization of FU
The sequence information derived from the FU cDNA
clones 1HFU, 2HFU and Ngo3689 (see Methods) allowed
the identification of the FU gene in a 200 kb BAC clone
(AC009974) from chromosome 2. The gene is localized to
2q35 at 217.56 Mb using the Ensembl [19] annotation.
The Ensembl gene prediction programs have identified
most, but not all (21 of 29 exons; the published FU [8]
predicts 26 exons) of the FU structure and named the gene
STK36 (serine/threonine protein kinase 36). Chromo-
some 2q35 is the locus of several genetically based disor-
ders. Both Syndactyly type 1 (SD1) and Brachydactyly
type A1 (BDA1) have been mapped to this region
[17,18,20]. Recently, the gene responsible for BDA1 has
been identified as IHH (Indian Hedgehog) one of the ver-
tebrate Hh homologues [21]. IHH is located in the vicinity
of FU on chromosome 2 (217.94 Mb) less than 400 kb
away. In order to determine if alterations of FU  are
responsible for SD1, the FU coding region (exons 3–29)
and the flanking intronic regions were sequenced using
genomic DNA from an affected member of an SD1 family
whose trait maps to the 2q34-q36 region [17] and an
unrelated control individual. No FU  mutations were
detected in this study, although three single nucleotide
polymorphisms were identified. These included a T to C
transition in intron 10, 17 bp 5' of exon 11 (IVS10-
17T>C), causing gain of a BstNI site, and a G to A transi-
tion in exon 16, 17 bp 5' of the end of the exonBMC Genomics 2004, 5:49 http://www.biomedcentral.com/1471-2164/5/49
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(1748G>A), causing substitution of glutamine for
arginine at amino acid 583 (R583Q) and loss of an AciI
site. The altered restriction sites created by these sequence
changes were tested in 44 CEPH unrelated individuals.
The results showed that both changes are normal
sequence variations as previously reported in the NCBI
SNP database. The third change was a G to A transition in
exon 27 (3008G>A), causing substitution of aspartic acid
for glycine at amino acid 1003 (G1003D). By sequencing
exon 27 in 8 affected and 6 unaffected members of the
SD1 family [17], the disease variant could be observed in
affected and unaffected members of the family, and a
homozygous healthy individual was found. This variant
has also been reported previously as a single nucleotide
polymorphism in the NCBI SNP database.
FU structure
None of the obtained cDNA clones contain sequence
from all FU exons, but they allow determination of the
exon-intron organization of FU. Figure 1 shows the struc-
ture of the FU gene. The cDNA clones are outlined to
account for the predicted structure. Only clone 1HFU and
Ngo3689 contain exons from the 5'non-coding region. To
the 5' side of the sequence encoded by exon 3 these clones
are different, indicating that alternative 5' untranslated
regions (UTR) from different exons can be used. Exons 3
to 9 encode the N-terminal kinase domain. None of the
cDNA clones encodes the FU protein that has previously
been described [8]. 1HFU lacks the sequence encoded by
exon 8, which results in a frame shift and a premature ter-
mination of translation. However, it cannot be unambig-
uously excluded that this may encode a very short protein
isoform having only a partial kinase domain. 1HFU also
includes the sequence from exon 13, which encodes an in
frame stop codon. Neither Ngo3689 nor 2HFU contain
the sequence encoded by exon 13. It is suggested that
inclusion of exon 13 gives rise to a shorter protein (S-FU)
of 474 residues, encode by exons 3 to 13. The previously
described [8] long form of FU (L-FU) having 1315 resi-
dues is encoded by exons 3 to 29 without inclusion of
exon 13. An additional alternative splice variant is sug-
gested from the Ngo3689 clone. The first 63 bp of the
sequence in exon 24 are missing. This results in a protein
that is 21 residues shorter than L-FU (encoded by exons 3
to 29 without exon 13 and the 63 bp). Since almost all of
the sequence from exon 24 is missing (only 18 bp are left)
this isoform is termed L-FU∆24. The Ngo3689 clone also
contains all the 289 bp from intron 17, but whether this
represents a true alternative splice variant is doubtful.
Multi tissue array and northern blot analyses
A tissue array with poly A+ RNA from 72 human tissues
was hybridized with a labeled probe 3' of the kinase
domain. It was clear from this array that all examined tis-
sues express FU to some extent. The highest amount of FU
transcripts were detected in testis and pituitary (not
shown). This is in agreement with the previous results by
Northern blotting, showing highest FU expression in tes-
tis [8]. This analysis revealed that most tissues express an
approximately 5 kb transcript [8]. The Northern blot anal-
ysis was here repeated with a larger number of tissues and
a probe containing a 3' portion of the gene (exon 28). Fig-
ure 2 shows results of the three different Northern blots
used. Here the transcripts are estimated to be a bit larger
than the reported 5 kb, generally in the range of 6 to 7 kb.
It should be emphasized that the identified cDNA clones
are approximately 5 kb and that this seems closer to the
correct sizes of transcripts, though they may appear larger
on the Northern blots. Adult skeletal muscle, thymus,
spleen, liver, small intestine, placenta, lung and leuko-
cytes show a faint 6.5 kb band. However, the adult tissues
brain, heart, colon and thyroid express a shorter transcript
of 6 kb. Adrenal seems to preferentially express a band in
the 6.5 to 7 kb range. In pancreas, fetal brain and fetal kid-
ney it appears that at least two bands are expressed in the
range from 6 to 7 kb. Besides, mRNA from fetal brain and
lung also give rise to a band of much larger size around
9.5 kb. It is not clear if this constitutes a transcript that has
not been fully processed, or whether it may contain
sequences from as yet unidentified exons, for instance
unknown 5'UTRs. Fetal lung and liver clearly preferen-
tially express transcripts of different sizes, 7 and 6 kb
respectively. It is confirmed that adult testis shows the
highest expression but also pancreas, kidney, fetal brain
and kidney stand out, in agreement with the previously
reported Northern analysis [8]. Since one major alterna-
tive splicing event seems to involve exon 13, we attempted
to evaluate the tissue specificity of this. A probe contain-
ing only the exon 13 sequence was used in hybridization
of the Northern blots. This resulted in smeary bands irre-
spective of the hybridization conditions used (not
shown). A likely explanation is that the probe is too short
to achieve high specificity hybridization, or perhaps the
transcripts containing exon 13 are degraded much faster,
possibly due to the process of nonsense mediated decay
[22].
Nested PCR analyses
To examine more specifically the expression of exons that
are involved in alternative splicing events, nested PCR was
performed on cDNA probes generated from whole tissue
RNA by reverse transcription. Sequences containing seg-
ments including exons 8, 13 and 24 were amplified and
analyzed on agarose gels (Fig. 3). It was not possible to
detect transcripts that lack exon 8 (Fig. 3, panel A). In con-
trast, it appears that transcripts both with and without
exon 13 are present (Fig. 3, panel B). Expression of tran-
scripts without exon 13 is clearly most prevalent in all tis-
sues. The expression of the longer form seems to be
proportional to the expression of the shorter form. ThisBMC Genomics 2004, 5:49 http://www.biomedcentral.com/1471-2164/5/49
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indicates that this splicing event is not subjected to any
significant tissue specific regulation. However, since a
detectable amount of transcripts including exon 13 are
present, it is likely that S-FU is also expressed in the tis-
sues. The analysis of alternative splicing of the part
encoded by exon 24 turned out to be difficult and several
primer pairs were tested before reliable results could be
obtained (Fig. 3, panel C). Interestingly, the examined tis-
sues show very different expression patterns, suggesting
that alternative splicing in this case is a regulated event.
Most tissues express all of exon 24 but in small intestine
and prostate clear expression of a transcript without the
63 bp is observed, and in testis expression of transcripts
both with and without this segment is found. Sequence
analysis shows that the 63 bp segment is likely to encode
part of a leucine zipper domain and therefore a putative
protein interaction may be lost in this isoform (L-FU∆24).
Functional analyses of FU isoforms
Investigations into the ability of FU isoforms to regulate
GLI transcription factors and SUFU has here been initi-
ated by expression of both L-FU and S-FU as well as 2HFU,
which does not have a full kinase domain, in HEK293
cells. The 293 cells, unlike the previously used C3H/10T½
cells [8], do not have a complete Hedgehog signaling
pathway. Thus, it is possible to determine if FUs have
direct effects on GLI proteins as it was done for SUFU [5].
The assay is based on the induction of a luciferase reporter
construct having 12 consecutive binding elements for GLI
transcription factors [5]. In all transfection assays GLI1
was able to induce the luciferase reporter 100–250 fold,
whereas GLI2 induced the reporter some 15–30 fold,
depending on cell density and the amount of construct
used. Figure 4 shows the results of these expression analy-
ses. As shown previously [5] SUFU has a strong inhibitory
FU gene structure Figure 1
FU gene structure. All sequenced segments of the available FU cDNA clones (1HFU, 2HFU and Ngo3689) were identified in 
a BAC clone (AC009974) from chromosome 2. This allowed the identification of the exonic sequences and thereby also the 
introns. The FU protein sequence [8] and translational analysis provided information about the role of different exons. Exons 1 
and 2 encode 5'UTRs shown in brown. Exon 3 contains the initiating ATG codon approximately in the middle (position 90–92 
from 5'end). Exons 3 to 9 encode the kinase domain shown in red. As judged from the cDNA clones the sequences encoded 
by exons 8, 13 and part of exon 24 are subjected to alternative splicing. Both exon 13 and 29 encode in frame stop codons. 
The cDNA clones end with a poly A+ tail at the same position starting 706 bp from the stop codon (TGA) in exon 29.
1                                                                29
ATG Stop
FU structure
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2                                                                29
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7                                                                29
FU cDNA clones
289 bp intronic seq
clone Ngo3689
1      3             7                  8                        13                             24         28            29
30 kbBMC Genomics 2004, 5:49 http://www.biomedcentral.com/1471-2164/5/49
Page 5 of 10
(page number not for citation purposes)
effect on GLI1. Moreover, a similar strong effect was seen
on GLI2 (Fig 4., panel A). The results presented are typical
for a large number of experiments and depend on the
amount of GLI and SUFU that is used. In contrast to the
strong effects seen with SUFU, none of the FUs revealed
major changes (Fig. 4, panel B and C). It is clear that the
FUs are not able to regulate GLI1 at all, though L-FU and
2HFU have a weak (2–3 fold) positive effect on GLI2. It
appears that L-FU has a slightly stronger effect than 2HFU.
This is qualitatively the same result as was obtained in
C3H/10T½ cells, where the L-FU was also compared to a
kinase-dead mutant and a 546 residue variant similar to S-
FU. Thus, in both cases there is no evidence that the kinase
domain is required for the activation of GLI2. Unlike the
previous analyses [8], it cannot be confirmed that FUs
have a direct effect on SUFU function (Fig. 4, panel D).
The inhibitory effect of SUFU on GLI1 is not relieved by
the addition of FU. The effect on GLI2/SUFU cannot be
distinguished from the effect on GLI2 alone, implying
that FU does not regulate SUFU but may only affect GLI2.
Since 293 cells lack components of the Hedgehog signal-
ing pathway, it is possible that an effect of L-FU on SUFU
[8] requires the presence and activity of additional
molecules.
Discussion
The FU gene
In the present paper, the FU gene was identified and its
structure determined. FU consists of 29 exons of which
exons 1 and 2 encode 5'UTRs, exon 3 contains the initiat-
ing ATG codon and exons 13 and 29 contain in frame stop
codons (Fig. 1). Exon 1 and 2 may serve as alternative first
exons, like the alternative exons 1, 1A and 1B found in the
PTCH1 gene [23]. Exons 3 to 9 encode the kinase domain.
This segment has strong similarity to Drosophila fu,
whereas the remaining C-terminal part has a much weaker
similarity [8]. Using the DIALIGN program [24] it is pos-
sible to align fu to L-FU in two regions in the C-terminal
part (not shown). These are largely encoded by exons 15–
16 and 22–29. This indicates that exons 10–14 and 17–21
may have been recruited to the FU gene during evolution.
Investigations of Syndactyly patient material
We investigated the possibility that FU  underlies SD1
based upon the fact that FU lies within the localization
interval for SD1 and that it is part of the Sonic Hedgehog
signaling pathway, which participates in digital patterning
[1]. Although three previously reported single nucleotide
polymorphisms were identified, we did not detect any
mutation in the FU coding region or flanking intronic
regions. While these results do not implicate FU in the
causation of SD1, it is possible that this disorder is caused
Northern blot analysis of FU expression in human tissues Figure 2
Northern blot analysis of FU expression in human tissues. Three commercially available Northern blots were hybrid-
ized with a labeled FU probe and analyzed by phosphorimaging. The blots have RNA from endocrine organs, other adult and 
fetal tissues as indicated. Size markers are shown to the left.
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by mutations in the noncoding regions not screened in
this study. Alternatively, SD1 could be caused by a
genomic rearrangement not identified by sequence analy-
sis, although no altered bands were detected in an affected
member of the SD1 family by Southern analysis using a
FU cDNA clone as probe (data not shown).
Expression analyses
Analyses of FU expression have shown that transcripts are
detected in all tissues examined. For the first time evi-
dence is presented showing that more than one transcript
can be expressed from this gene. The Northern blots
clearly show that FU transcripts of different sizes indeed
Analyses of alternative splicing by nested PCR Figure 3
Analyses of alternative splicing by nested PCR. Nested PCR was performed on cDNA from 8 tissues, over regions 
implicated to undergo alternative splicing. These are encoded by exons 8 (panel A), 13 (panel B) and 24 (panel C). Available 
cDNA clones either with or without these parts served as controls as indicated. The PCR products were analyzed on agarose 
gels as shown.
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exist. Here the transcripts are estimated to be slightly
bigger than previously reported and in some tissues more
than one transcript is evident. It is clear from the available
cDNAs and RT/PCR based transcript analyses that alterna-
tive splicing occurs. Additionally, it is also clear that differ-
ent 5'UTRs are present in the transcripts. At least two
protein isoforms, besides the previously described L-FU
[8], may be produced. The S-FU isoform is the one that
most dramatically differs from L-FU, consisting only of
the N-terminal one third of L-FU. S-FU expression results
from inclusion of exon 13 in the mature transcript. This
alternative splicing event was detected in all tissues exam-
ined and at an apparently constant ratio. Also a case of
regulated alternative splicing was detected by RT/PCR, but
with a much less dramatic impact at the protein level,
since it only results in the loss of 21 residues encoded by
exon 24. However, the expression reveals a possible tissue
specific regulation of this alternative splicing event. This
may well reflect that L-FU∆24 plays a biological role dif-
ferent from L-FU. Since it appears that the mRNA for L-
FU∆24 is not expressed in small intestine and prostate it
can be speculated that FU has a different role there, if a
leucine zipper is truly lost in L-FU∆24. It is intriguing that
testis appears to express transcripts both with and without
the 63 bp segment and is also the tissue with strongest
expression. Perhaps the expression of L-FU∆24 and L-FU
Figure 4
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Regulation of GLI induced transcriptional activity in trans- fected HEK293 cells Figure 4
Regulation of GLI induced transcriptional activity in 
transfected HEK293 cells. HEK293 cells were transfected 
with a GLI inducible luciferase reporter construct together 
with a GLI1 or GLI2 expression construct. The cells were 
also transfected with a β-galactosidase construct that served 
to correct for transfection efficiency and cell density. The 
effects of FU and SUFU were tested by cotransfecting FU and 
SUFU expression constructs and compared to effects with 
empty vectors. Panel A shows typical examples of SUFU 
effects on GLI1 and GLI2. Panel B shows typical examples of 
the effects of different FU constructs on GLI1 and GLI2; 
experiments that were performed in parallel are shown, to 
illustrate the different impact on the GLI proteins. L-FU is 
shown with squares, 2HFU with triangles and S-FU with cir-
cles. Panel C shows the impact of FU constructs (400 ng) on 
GLI1 and GLI2 as summarized by the results of at least 4 dif-
ferent experiments. Panel D shows the impact of FU con-
structs (400 ng) on SUFU inhibited GLI1 and GLI2 as 
summarized by the results of 3 different experiments. In 
these experiments the GLI induced transcriptional activity 
was inhibited to 20–40 % of the non-inhibited level by the 
addition of SUFU (i.e. 2½ to 5 fold inhibition). Relative activ-
ity (panel A) is given as compared to activity in mock trans-
fected cells and normalized activity (panel B-D) is given 
relative to activity in cells transfected with GLI and 
GLI+SUFU set to 1.BMC Genomics 2004, 5:49 http://www.biomedcentral.com/1471-2164/5/49
Page 8 of 10
(page number not for citation purposes)
together is linked to the function of Desert Hedgehog
which has been shown to have a particular role in sperma-
togenesis [25]. Whether interactions with GLI proteins,
SUFU or other components of the signaling pathway are
altered, and if this has any impact on GLI or SUFU activi-
ties, remains to be investigated. Certainly this adds
another variable to the complicated picture of Hedgehog
signaling and GLI regulation in vertebrates.
Functional investigations and perspectives
The assessment of functionality revealed that S-FU was
not able to regulate GLI1 or GLI2 when expressed in 293
cells. In contrast, both L-FU and a variant lacking a full
kinase domain (2HFU) were able to enhance GLI2
induced transcription. These results are qualitatively sim-
ilar to those previously reported in C3H/10T½ cells [8]. L-
FU and 2HFU were only able to enhance GLI2 activity 2
to 3 fold in 293 cells, whereas 5 to 8 fold inductions are
seen in C3H/10T½ cells. This may reflect the fact that the
latter cell line expresses additional components of the
Hedgehog signaling pathway, which are required for full
activity of FU. Unlike the previous investigations [8] it was
not possible to see an effect of L-FU on SUFU. Again this
difference may be explained by the various properties of
the cell lines used. Understanding the signaling events
downstream of SMO may reveal functional differences of
the proteins involved, as compared to their fruit fly coun-
terparts. Although SUFU inhibits GLI transcription factors
and su(fu) inhibits Ci, there are still striking differences.
As yet there have been no reports of a cos2 counterpart in
vertebrates. Instead it has been observed that FU interacts
with all GLI proteins and SUFU [8], even though fu does
not bind to Ci [26]. It has also been observed that both L-
FU and SUFU can be found in the nucleus [5-8], which
has not been observed for fu or su(fu). It is likely that both
FU and SUFU are shuttled in and out of the nucleus by
binding to GLI proteins [5,8]. Though basic activities of
both FU and SUFU in regulation of GLI have been con-
served, it also appears that significant differences from
their fruit fly counterparts exist. Clearly, FU is not having
an effect on GLI1 similar to the one seen on GLI2. Addi-
tional investigations are needed in order to establish the
role of FU in hedgehog signaling and GLI control. The role
of the different isoforms also remains to be elucidated.
These have to be tested individually for their regulation of
all GLI proteins and proteolytic products. Fu is known to
have at least two separate physiological functions in the
fly, one of which is dependent upon the kinase domain
[27]. Likewise, FU may well have two or more distinct
functions in signaling, represented by different domains,
isoforms and protein interactions.
Conclusions
FU is localized on chromosome 2q35 very close to IHH.
Though SD1 has been mapped to this region, we have not
identified a causative role for FU in this disorder. FU con-
sists of 29 exons of which 1 and 2 encode 5'UTRs and 3 to
9 encode a kinase domain. For the first time it is shown
that transcripts of different sizes are expressed and alterna-
tive splicing takes place, probably leading to the genera-
tion of different protein isoforms. FU protein is likely to
be involved in the Hedgehog signaling pathway since it
can enhance the activity of GLI2. In contrast, it has no
effect on GLI1 and an effect on SUFU cannot be observed
in 293 cells.
Methods
The FU cDNA clones
Two almost full-length human FU clones were identified
in the Incyte database. Both 1HFU and 2HFU were cloned
in the vector pINCY. A third clone was available from
Kazusa DNA Research Institute (Chiba, Japan) and
termed Ngo3689 (Gene name KIAA1278). This clone was
in the vector pBluescript II SK+. The human BAC clone
AC009974 was obtained from Research Genetics (Hunts-
ville, AL). The human GLI, human SUFU, 12GLI-RE-luci-
ferase reporter and β-galactosidase vectors have been
described previously [5].
FU cDNA subcloning
Expression constructs for different isoforms of FU was
obtained by direct PCR or extension overlap PCR, using
end-primers having specific restriction sites and the high
fidelity VentR DNA polymerase (New England Biolabs,
Beverly, MA). The cDNA for the long form of FU (L-FU)
was subcloned into pCDNA3.1-HisB using the NotI and
XbaI sites. 2HFU and the short FU (S-FU) cDNAs were
subcloned into pCDNA3.1-HisC using the KpnI and XbaI
sites.
DNA sequencing and analyses
All PCR generated products were analyzed by DNA
sequencing. The Big-Dye Terminator Cycle Sequencing kit
(Applied Biosystems, Foster City, CA) was used according
to instructions. Sequencing was performed at CyberGene
AB (Huddinge, Sweden). Sequence alignments were done
using the DIALIGN program [24] available at the BiBiServ
from University of Bielefeld, Germany. Sequence infor-
mation of proteins, clones and chromosomes were
obtained from the Swiss-Pro [28], Entrez [29] and
Ensembl [19] databases.
Analyses of genomic DNA from family members with SD1
After informed consent was obtained, blood was taken
from affected and unaffected family members and DNA
extracted from peripheral blood leukocytes according to
standard methods. Intronic primers were designed to
amplify exons 3–29 of FU  either as single exons with
flanking intronic sequences or as products containing two
exons with flanking intronic sequence and the completeBMC Genomics 2004, 5:49 http://www.biomedcentral.com/1471-2164/5/49
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intervening intron. The primer sequences can be obtained
upon request. PCR was performed in a standard fashion
and products were sequenced using either the Thermose-
quenase CyTM5.5 Dye Terminator or DYEnamic ET Dye
Terminator Cycle Sequencing kits (Amersham Bio-
sciences, Piscataway, NJ). Electrophoresis and analysis
were performed on either an Automated Laser Fluores-
cence (ALF) DNA sequencer or MegaBACE DNA
sequencer (Amersham Biosciences) after purification with
Autoseq columns (Amersham Biosciences). For exon 27,
the PCR product was purified using the enzymatic ExoI-
SAP purification method, sequenced using the Terminator
Cycle Sequencing kit (Amersham Pharmacia Biotech) and
analysed on an ABI 3100 genetic analyzer (Applied Bio-
systems). PCR products containing exon 11 or exons 15/
16 were digested with BstNI or AciI, respectively, and the
bands resolved on 3–4% agarose gels to confirm sequence
changes in the patient with SD1 and to determine their
frequency in a panel of 44 CEPH individuals.
Northern blot analysis
Commercially available Human MTN 12-lane Blot 2,
Human Fetal MTN Blot II and Human Endocrine System
MTN Blot Northern blots (Clontech, Paolo Alto, CA) were
obtained and used with PCR generated hybridization
probes. DNA probes were made by direct PCR, amplifying
the sequences corresponding to exon 13 and 28. The gen-
erated fragments were then labeled with 32P-ATP using the
High Prime DNA labeling kit (Boehringer Mannheim,
Mannheim, Germany) according to instructions. Hybrid-
ization of Northern blots was done with labeled DNA
probes in ExpressHyp (Clontech) at 68°C according to
instructions. The blots were then analyzed with a Fujix Bas
2000 phosphoimager (Fuji Photo Film, Tokyo, Japan).
Expression analysis by nested PCR
The expression of exon 8, 13 and 24 sequences in mRNA
was assessed by nested PCR on RT/PCR generated cDNA
samples from eight different tissues as provided in
Human Multi Tissue cDNA Panel II (Clontech). Two sets
of primers were made for each exon to be investigated.
The outer pairs were used in a first PCR using 5 µl of the
cDNA and Vent polymerase. In a second PCR 0.5 µl of the
first PCR products was used together with the inner
primer pairs. These pairs were also used for PCR of FU
cDNA clones that served as controls. The primer pairs are
listed in Table 1. The PCR reactions were performed using
95°C for 1 min denaturation, elongation at 72°C and 40
cycles. The exon 8 and 13 sequence PCRs were performed
using 60°C 1 min annealing and 1 min elongation. The
exon 24 sequence PCRs were performed using 59°C 1
min annealing and 1 min 30 sec elongation.
Reporter gene assays
The cDNA clones were used in transfections of HEK293
cells in 24 well culture plates. Basically this was done as
previously described [5]. In short, the 293 cells were trans-
fected using Superfect Transfection Reagent (Clontech),
with 100 ng of the luciferase reporter and β-galactosidase
as well as different amounts and combinations of GLI, FU
and SUFU constructs. For every assay there was a corre-
sponding control with an equal amount of empty vector.
The cells were harvested 24 hours after transfection with
50 µl of lysis buffer from the Galacto-Light kit (Applied
Biosystems). Of this was 10 µl used for β-galactosidase
assay and the rest for luciferase assay using the Luciferase
Assay kit (BioThema, Dalarö, Sweden). Analyses were
done on a Microplate Luminometer (Berthold Detection
System, Pforzheim, Germany).
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